Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis

Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of bleeding in the first 6 months. Most of the guidelines propose to integrate the bleeding risk in the choice of therapies. Thrombin generation assay (TGA) reflects an overall hemostatic response and could be a useful biomarker. Proven on the thrombotic side in the CAT population, useful in the assessment of the bleeding risk of hemophiliac patients, the TGA is emerging

Trial Details

NCT ID
NCT06386107
Phase
NA
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Thrombin Generation Assay (TGA)
Locations (sample)
  • Clermont-Ferrand, France|45.77969,3.08682
  • Grenoble, France|45.17869,5.71479
  • Lyon, France|45.74906,4.84789
  • Saint-Etienne, France|45.43389,4.39

Key Eligibility Criteria

  • Patients with active cancer, as defined by current French recommendations (Mahé I et al Rev Mal Respir 2021)
  • Presenting acute proximal deep vein thrombosis of the lower limb (DVT) and/or proximal pulmonary embolism (at least segmental) (PE), confirmed by o…
  • No contraindication for anticoagulant treatment at a curative dose at the time of inclusion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →